• 22. November 2024

ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions

ByISA Pharmaceuticals

Apr 14, 2016
– ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer
– Optimum immunotherapy window in cancer identified

Teile den Beitrag mit Freunden